Intravitreal Bevacizumab for Macular Edema From Idiopathic Juxtafoveal Retinal Telangiectasis

Suk J. Moon, Adam Berger, Michael J. Tolentino, David Misch

Ophthalmic surgery, lasers & imaging retina · 2007 · 34 citations · 10 references

Concepts

Abstract

<P>To assess the potential visual benefit of intravitreal bevacizumab in a patient with idiopathic juxtafoveal retinal telangiectasis refractory to focal laser treatment, an intravitreal injection of bevacizumab (1.25 mg) was given. Within 1 week, visual acuity improved from 20/50 to 20/25 and optical coherence tomography demonstrated complete resolution of macular edema. There was no adverse effect. The macular edema recurred after 3 months, requiring a repeat injection of bevacizumab with subsequent resolution of macular edema. An intravitreal injection of bevacizumab may provide potential short-term visual benefit in patients with macular edema from idiopathic juxtafoveal retinal telangiectasis. [<CITE>Ophthalmic Surg Lasers Imaging</CITE> 2007;38:164-166.]</P> <H4>AUTHORS</H4> <P>From The Center for Retina and Macular Disease, Winter Haven, Florida.</P> <P>Accepted for publication January 10, 2007.</P> <P>Address correspondence to Suk J. Moon, MD, The Center for Retina and Macular Disease, 250 Avenue K, SW, Suite 200, Winter Haven, FL 33880.</P>

References

10